問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberM16-067
NCT Number(ClinicalTrials.gov Identfier)NCT03398148
Completed

2018-01-01 - 2023-05-12

Phase II/III

Recruiting5

Terminated1

ICD-10K51

Ulcerative colitis

ICD-9556.9

Ulcerative colitis, unspecified

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Trial Applicant

    AbbVie

  • Sponsor

    AbbVie Biopharmaceuticals GmbH Taiwan Branch

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator Ming-Chih Hou Digestive System Department
Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator 凃佳宏 Digestive System Department
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator 林敬斌 Division of General Internal Medicine
Chung Shan Medical University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator CHUNG-HSIN CHANG Digestive System Department
Taichung Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jen-Wei Chou Digestive System Department
China Medical University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chia-Jung Kuo Digestive System Department
Linkou Chang Gung Medical Foundation

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Condition/Disease

Moderately to Severely Active Ulcerative Colitis

Objectives

Study M16-067 comprises two sub-studies: The objective of Sub-Study 1 (Phase 2b induction) is to characterize the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC) and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2 (Phase 3 induction). At the time of this amendment, Sub-study 1 has closed enrollment and all subjects in the double-blind, placebo-controlled portion of the study have completed induction. The objective of Sub-Study 2 (Phase 3 induction) is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

Test Drug

Risankizumab

Active Ingredient

risankizumab

Dosage Form

IV / SC

Dosage

1800 mg, 1200 mg, 600 mg, 360 mg, 180 mg

Endpoints

Primary Endpoint:
Proportion of subjects with clinical remission per Adapted Mayo score at Week 12.
Sub-Study 1 Ranked Secondary Endpoints:
1. Proportion of subjects with endoscopic improvement at Week 12
2. Proportion of subjects achieving clinical remission per Full Mayo score (defined as a Full Mayo
score ≤ 2 with no subscore > 1) at Week 12 in subjects with a Full Mayo score of 6 to 12 at Baseline
3. Proportion of subjects achieving clinical response per Adapted Mayo score at Week 12
4. Proportion of subjects achieving clinical response per Partial Adapted Mayo score at Week 4
5. Proportion of subjects with endoscopic remission at Week 12
6. Proportion of subjects with hospitalizations through Week 12
7. Proportion of subjects with mucosal healing at Week 12
8. Change from Baseline to Week 12 in UC-Symptom Questionnaire (UC-SQ)
9. Change from Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ)
10. Change from Baseline to Week 12 in Short Form-36
11. Change from Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-Fatigue)
12. Proportion of subjects with UC-related surgeries through Week 12
Sub-Study 2 Ranked Secondary Endpoints:
1. Proportion of subjects achieving clinical remission per Full Mayo score (defined as a Full Mayo
score ≤ 2 with no subscore > 1) at Week 12 in subjects with a Full Mayo score of 6 to 12 at
Baseline
2. Proportion of subjects achieving clinical response per Adapted Mayo score at Week 12
3. Proportion of subjects achieving clinical response per Partial Adapted Mayo score at Week 4
4. Proportion of subjects who reported no abdominal pain at Week 12
5. Proportion of subjects who reported no bowel urgency at Week 12
6. Proportion of subjects with endoscopic remission at Week 12
7. Proportion of subjects with endoscopic improvement at Week 12
8. Change from Baseline to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) total
score
9. Change from Baseline to Week 12 in Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-Fatigue)
10. Proportion of subjects with histological endoscopic improvement of the mucosa at Week 12
11. Proportion of subjects who reported no nocturnal bowel movements at Week 12
12. Proportion of subjects who reported no tenesmus at Week 12
13. Change from Baseline to Week 12 in number of fecal incontinence episodes per week
14. Change from Baseline to Week 12 in number of days per week with sleep interrupted due to UC
symptoms
15. Proportion of subjects achieving clinical response per Adapted Mayo score at Week 12 in subjects
with pancolitis at Baseline
16. Proportion of subjects with UC-related hospitalizations through Week 12
17. Change from Baseline to Week 12 in Short Form-36 (SF-36)

Inclution Criteria

1. Males or females ≥ 18 and ≤ 80 years of age, or minimum age of adult consent according to local
regulations at the Baseline Visit. In addition, for Sub-Study 2 only: Where locally permissible,
subjects 16 to < 18 years of age who meet the definition of Tanner Stage 5 for development (refer to
the Appendix G) at the Baseline Visit.
2. Confirmed diagnosis of UC for at least 3 months prior to Baseline. Appropriate documentation of
biopsy results consistent with the diagnosis of UC or in the assessment of the Investigator, must be
available.
3. Active UC with an Adapted Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3
(confirmed by central review).
4. Demonstrated intolerance or inadequate response to one or more of the following categories of
drugs: aminosalicylates, oral locally acting steroids, systemic steroids (prednisone or equivalent),
immunomodulators, and/or biologic therapies or tofacitinib.
 Demonstration of intolerance requires no minimum dose or duration of use.
 Inadequate response is defined as outlined below:
o Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, balsalazide):
 Signs and symptoms of persistently active disease, in the opinion of the Investigator,
during a current or prior course of at least 4 weeks of treatment with 2.4 g/day
mesalamine (2 g/day if controlled release), 4 g/day sulfasalazine, 1 g/day olsalazine,
or 6.75 g/day balsalazide,
o Oral locally acting steroids (e.g., budesonide, beclomethasone):
 Signs and symptoms of persistently active disease, in the opinion of the Investigator,
during or after a course of at least 4 weeks of treatment with 9 mg/day budesonide or
5 mg/day beclomethasone,
OR
 Inability to taper oral budesonide to at or below 6 mg/day without recurrent active
disease,
o IV or Oral systemic steroids (prednisone or equivalent):
 Signs and symptoms of persistently active disease, in the opinion of the Investigator,
during or after tapering of at least one regimen consisting of a dose equivalent to
prednisone ≥ 40 mg/day orally for 3 weeks or intravenously for 1 week,
OR
 Inability to taper oral systemic steroids to at or below a dose equivalent to prednisone
10 mg/day without recurrent active disease,
o Immunomodulators:
 Signs and symptoms of persistently active disease, in the opinion of the Investigator,
during a current or prior course of at least 90 days of treatment with one or more of
the following:
o AZA: ≥ 2.0 mg/kg/day rounded to the nearest available tablet or half tablet
formulation (≥ 1 mg/kg/day for subjects in Japan, Korea, Taiwan, Singapore, or
China) (or a documented 6-TGN level of ≥ 230 pmol/8 × 108 RBC)
o 6-MP: ≥ 1 mg/kg/day rounded to the nearest available tablet or half tablet
formulation (≥ 0.6 mg/kg/day for subjects in Japan, Korea, Taiwan, Singapore, or
China) (or a 6-TGN level of ≥ 230 pmol/8 × 108 RBC)
o MTX: ≥ 15 mg/week subcutaneous (SC) or intramuscular (IM)
 Note: Oral MTX use is allowed during the study, however prior or current
use of oral MTX is not sufficient for inclusion into the study
o Tacrolimus: (for Japan, Taiwan and other countries in Asia with local treatment
guidelines that include tacrolimus) documented trough level 5 - 10 ng/mL
 Biologic Therapies and tofacitinib for UC: Signs and symptoms of persistently active
disease despite a history of one or more of the following:
o At least one 6-week induction regimen of infliximab (≥ 5 mg/kg intravenous [IV]
at Weeks 0, 2, and 6),
o At least one 4-week induction regimen of adalimumab (one 160 mg SC dose at
Week 0, followed by one 80 mg SC dose at Week 2 [or one 80 mg SC dose at
Week 0, followed by one 40 mg SC dose at Week 2, in countries where this
dosing regimen is approved]),
o At least one 4-week induction regimen of golimumab (200 mg SC at Week 0 and
100 mg SC at Week 2),
o At least one 6-week induction regimen of vedolizumab (300 mg IV at Weeks 0, 2,
and 6),
o At least one 8-week induction regimen of tofacitinib (10 mg PO twice daily)
 Recurrence of symptoms during scheduled maintenance dosing following prior
clinical benefit of the above biologics
 Note: Subjects who discontinued biologics or tofacitinib for reasons other than
inadequate response as defined above or intolerance (e.g., change of insurance) must
meet the criteria for intolerance or inadequate response to aminosalicylates, oral
locally acting steroids, systemic steroids (prednisone or equivalent), and/or
immunomodulators as defined above
5. If female, subject must meet the criteria as stated in Section 5.2.4 of this protocol Contraception
Recommendations. Females of childbearing potential must have a negative serum pregnancy test
result during Screening, and a negative urine pregnancy at Baseline. Females of non-childbearing
potential (either postmenopausal or permanently surgically sterile as defined in Section 5.2.4) during
Screening do not require pregnancy testing at Baseline.
6. Subject must be able and willing to give written informed consent and to comply with the
requirements of this study protocol. In Japan, if the subject is < 20 years old, a subject's parent or
legal guardian must be willing to give written informed consent.

Exclusion Criteria

1. Subject with a current diagnosis of Crohn's disease (CD), IBD-unclassified (IBD-U) or a history of
radiation colitis or ischemic colitis.
Concomitant Medications and Treatments
2. Subject on oral UC-related antibiotics who has not been on stable doses for greater than, or
discontinued within, 14 days prior to Baseline.
3. Subject on oral aminosalicylates who has not been on stable doses for greater than, or discontinued
within, at least 14 days prior to Baseline.
4. Subject taking oral corticosteroids:
 Budesonide > 9 mg/day
 Beclomethasone > 5 mg/day
 Prednisone or equivalent > 20 mg/day
 Or has not been on the current course for ≥ 14 days prior to Baseline and on a stable dose for
≥ 7 days prior to Baseline
5. Subject on immunomodulators (AZA, 6-MP, MTX) who:
 Has not been on the course for ≥ 42 days prior to Baseline, and
 Has not been on a stable dose for ≥ 35 days prior to Baseline
Medications and Treatments During the Screening Period
6. Subject who received IV anti-infectives within 35 days prior to Baseline visit or oral anti-infectives
(non-UC-related) within 14 days prior to the Baseline visit. This does not apply to TB prophylaxis.
7. Subject who received any parenteral nutrition within 35 days prior to Baseline.
8. Subject who received any live bacterial or viral vaccination within 35 days (8 weeks for Japan) prior
to Baseline.
9. Subject who received cyclosporine, tacrolimus, or mycophenolate mofetil within 35 days prior to
Baseline.
10. Subject who received fecal microbial transplantation within 35 days prior to Baseline.
11. Subject who received any:
 approved biologic agent (e.g., infliximab, adalimumab, golimumab, vedolizumab) within
8 weeks prior to Baseline or tofacitinib within 35 days prior to Baseline
12. Subject with prior exposure to p40 inhibitors (e.g., ustekinumab [Stelara]) or p19 inhibitors
(e.g., risankizumab).
13. Subject has been taking combination of two or more of the following oral budesonide, oral
beclomethasone, and/or oral prednisone (or equivalent) simultaneously, with the exception of
inhalers, within 14 days prior to Screening or during the Screening period.
14. Subject who received IV/intramuscular corticosteroids within 14 days prior to Screening or during
the Screening period.
15. Subject who received therapeutic enema or suppository (i.e., rectal aminosalicylates/corticosteroids),
other than required for endoscopy, within 14 days prior to Screening or during the Screening period.
16. Subject who received apheresis (e.g., Adacolumn apheresis) ≤ 60 days prior to Screening or during
the Screening period.
17. Subject who has concomitant cannabis use either recreational or for medical reasons within 14 days
prior to Baseline or any history of clinically significant drug, or alcohol abuse in the last 12 months.
UC Related
18. Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy
19. Subject with currently known complications of UC such as:
 fulminant colitis,
 toxic megacolon,
 previous colectomy (total or subtotal),
 or any other manifestation that might require surgery while enrolled in the study.
20. Subject with ostomy or ileoanal pouch.
Safety
21. Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study
drugs or the ingredients of Chinese hamster ovary (CHO).
22. Subjects with the following chronic or active infections:
 Active, chronic, or recurrent infection that based on the Investigator's clinical assessment makes
the subject unsuitable candidate for the study,
 Infection with C. difficile toxin as identified during Screening,
 Known infection with an intestinal pathogen
 Are infected with human immunodeficiency virus (HIV),
 QuantiFERON®-TB test or Purified Protein Derivative (PPD) skin test, or both, according to
local guidelines, will be performed during Screening. QuantiFERON®-TB test is preferred for
subjects who received BCG vaccination or were exposed to other Mycobacteria species.
Subjects with a positive test result (or indeterminate results that have been repeated) may
participate in the study if further work up (according to local practice/guidelines) establishes
conclusively that the subject has no evidence of active tuberculosis. Subjects with a history of
active TB who have documented completion of a full course of anti-TB therapy may be allowed
to enter the study after consultation with the AbbVie TA MD). If latent TB is established, TB
prophylaxis/treatment should be initiated and maintained according to local country
guidelines.
 Have active hepatitis B or hepatitis C defined as:
o HBV: hepatitis B surface antigen (HBs Ag) positive (+), or detected sensitivity on the
HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for
hepatitis B core antibody (HBc Ab) positive subjects;
o HCV: HCV ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody
(HCV Ab)
23. Subject with a previous history of dysplasia of the gastrointestinal tract or found to have dysplasia,
other than completely removed low-grade dysplastic lesions, in any biopsy performed during the
Screening endoscopy.
24. Subject with a known history of lymphoproliferative disease, including lymphoma, or signs and
symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or
splenomegaly.
25. Subject with or history of malignancy other than a successfully treated non-metastatic cutaneous
squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
26. Subject who has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine,
disorder or symptoms thereof.
27. Female subjects who is pregnant, breastfeeding, or is considering becoming pregnant during the
study or for approximately 140 days after the last dose of study drug.
28. Subject who has any condition including any physical, psychological, or psychiatric condition,
which in the opinion of the Investigator, would compromise the safety of the subject or the quality
of the data and renders the subject an unsuitable candidate for the study.
29. Screening laboratory and other analyses show any of the following abnormal results:
 Aspartate transaminase (AST), alanine transaminase (ALT) > 2 × upper limit of the reference
range;
 White blood cell (WBC) count < 3.0 × 109
/L;
 Total bilirubin ≥ 2 mg/dL; except for subjects with isolated elevation of indirect bilirubin
relating to Gilbert syndrome;
 Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal
Disease (MDRD) formula < 30 ml/min/1.73 m2
.
 Hemoglobin < 8 g/dL
 Platelets < 100,000/µL
Safety (Continued)
 Positive serum pregnancy test at the Screening visit or positive urine pregnancy test at the
Baseline visit.
30. No known active COVID-19 infection. If a subject has signs/symptoms suggestive of COVID-19,
they should undergo molecular (i.e., PCR) testing to rule out SARS-CoV-2 infection.
 Subjects who do not meet COVID-19 eligibility criteria must be screen failed and may only
rescreen after they meet the following criteria:
 Symptomatic subjects: At least 14 days have passed since recovery, defined as resolution of
fever without use of antipyretics and improvement in symptoms
 Asymptomatic subjects: At least 14 days have passed since the first positive molecular (i.e.,
PCR) test result.
Laboratory values can be re-tested once during the screening period. If the re-tested lab value(s)
remain(s) exclusionary, the subject will be considered a screen failure. Redrawing samples if
previous samples were unable to be analyzed would not count as a retest since previous result was
never obtained.

The Estimated Number of Participants

  • Taiwan

    12 participants

  • Global

    720 participants

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB